EMA AuthorisedEuropean Union
First EU Medicine for Early Brain ALD in Boys Ages 2–12
Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)
EC marketing authorisation 21 Sep 2026 under exceptional circumstances; first pharmacological cALD door in the EU
This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on…